Marketing of Eli Lilly Drugs Faces New Probe
From Associated Press
Eli Lilly & Co., already under federal investigation for the way it promoted an osteoporosis drug, said it faced a new federal probe of its marketing practices.
The Indianapolis-based company said it believed the new probe also probably focuses on the osteoporosis drug Evista, as well as its top seller, antipsychotic drug Zyprexa, and antidepressant Prozac.
Lilly, one of several drug makers to come under federal scrutiny over marketing issues, said the U.S. attorney for the Eastern District of Pennsylvania has begun a civil inquiry.
